At a glance
ClinicalIndex Comparison RecordPhase 2Active· 31 enrolled
Drug / intervention
Sacituzumab Govitecandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
In Brief
A Phase 2 clinical trial evaluating Sacituzumab Govitecan for Prostate Cancer. Active but no longer recruiting, targeting 31 participants across 3 sites.
Detailed Summary
This study will investigate the safety and efficacy of Sacituzumab Govitecan in patients with metastatic castration-resistant prostate cancer progressing on second generation androgen receptor (AR) directed therapy (e.g., enzalutamide, darolutamide, apalutamide and/or abiraterone).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Gilead Sciences
Timeline
Phase 2Active
201920202021202220232024202520262027
Enrollment StartOct 2018
First PostedOct 2018
Primary CompletionApr 2024
TodayJul 2026
Study CompletionSep 2027
First PostedOct 31, 2018
Enrollment StartOct 24, 2018
Primary CompletionApr 18, 2024
Study CompletionSep 1, 2027
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 7.7 years ago
Interventions
Sacituzumab Govitecandrug
Sacituzumab Govitecan is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.